IRIS
SANTARPIA, Mariacarmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.206
EU - Europa 6.628
AS - Asia 3.736
SA - Sud America 1.355
Continente sconosciuto - Info sul continente non disponibili 437
AF - Africa 134
OC - Oceania 10
Totale 19.506
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.954
RU - Federazione Russa 3.428
SG - Singapore 1.487
BR - Brasile 1.149
CN - Cina 1.006
IE - Irlanda 673
IT - Italia 638
SE - Svezia 539
HK - Hong Kong 399
VN - Vietnam 297
GB - Regno Unito 293
PL - Polonia 215
DE - Germania 204
FR - Francia 176
FI - Finlandia 148
IN - India 111
CA - Canada 99
UA - Ucraina 94
BD - Bangladesh 92
AR - Argentina 61
ID - Indonesia 49
AT - Austria 48
MX - Messico 45
IQ - Iraq 44
EC - Ecuador 42
ZA - Sudafrica 38
TR - Turchia 33
CO - Colombia 30
ES - Italia 28
MA - Marocco 28
NL - Olanda 26
JP - Giappone 25
BE - Belgio 22
UZ - Uzbekistan 22
VE - Venezuela 22
CR - Costa Rica 21
AE - Emirati Arabi Uniti 16
IL - Israele 16
JM - Giamaica 15
PK - Pakistan 15
TN - Tunisia 15
CL - Cile 14
MY - Malesia 13
PY - Paraguay 13
KE - Kenya 12
CZ - Repubblica Ceca 11
GT - Guatemala 11
PE - Perù 11
EE - Estonia 10
GR - Grecia 10
NP - Nepal 10
SA - Arabia Saudita 10
AZ - Azerbaigian 9
DO - Repubblica Dominicana 9
KZ - Kazakistan 9
SC - Seychelles 9
AL - Albania 8
AU - Australia 8
PH - Filippine 8
RS - Serbia 8
SV - El Salvador 8
TH - Thailandia 8
BG - Bulgaria 7
LT - Lituania 7
PA - Panama 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
BO - Bolivia 6
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
GP - Guadalupe 6
HN - Honduras 6
JO - Giordania 6
KG - Kirghizistan 6
KR - Corea 6
NI - Nicaragua 6
AM - Armenia 5
CH - Svizzera 5
CW - ???statistics.table.value.countryCode.CW??? 5
OM - Oman 5
BY - Bielorussia 4
IR - Iran 4
MD - Moldavia 4
BB - Barbados 3
DK - Danimarca 3
LB - Libano 3
SK - Slovacchia (Repubblica Slovacca) 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
CG - Congo 2
EU - Europa 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
MN - Mongolia 2
MT - Malta 2
Totale 19.036
Salva come PNG Salva come JPEG
Città #
Ashburn 1.150
Moscow 1.014
Singapore 781
Dublin 672
Dallas 582
San Jose 471
Chandler 422
Hong Kong 396
Nyköping 306
Beijing 294
Council Bluffs 257
Jacksonville 232
Warsaw 209
Messina 184
The Dalles 180
Los Angeles 167
Lancaster 144
Princeton 133
Medford 122
New York 110
Lauterbourg 107
Dearborn 98
Cambridge 93
Des Moines 91
Santa Clara 87
Ho Chi Minh City 84
São Paulo 78
Ann Arbor 77
Munich 70
Rome 63
Hanoi 60
Redondo Beach 58
Atlanta 49
Rio de Janeiro 47
Buffalo 46
Guangzhou 46
Tianjin 45
North Bergen 43
Turku 43
Boardman 42
Orem 41
Chicago 38
Wilmington 37
Vienna 35
Brooklyn 34
Dong Ket 32
Milan 32
Phoenix 31
Frankfurt am Main 29
Montreal 29
Seattle 29
Jakarta 28
Shenyang 28
Jinan 27
San Mateo 26
Houston 24
Nuremberg 23
Quito 23
Shanghai 23
Tokyo 23
Brussels 22
Pune 22
Johannesburg 21
Denver 20
San Francisco 20
San José 20
Naples 19
Tashkent 19
Belo Horizonte 18
Brasília 18
Columbus 18
London 18
Chennai 17
Düsseldorf 17
Baghdad 16
Catania 16
Curitiba 16
Porto Alegre 16
Boston 15
Haiphong 14
Mumbai 14
Nanjing 14
Salvador 14
Washington 14
Amsterdam 12
Biên Hòa 12
Da Nang 12
Dhaka 12
Helsinki 12
Memphis 12
Stockholm 12
Toronto 12
Woodbridge 12
Zhengzhou 12
Bexley 11
Campinas 11
Charlotte 11
Goiânia 11
Hebei 11
Hyderabad 11
Totale 10.349
Salva come PNG Salva come JPEG
Nome #
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System 270
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 254
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach 250
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 246
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 243
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 242
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 235
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 229
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 217
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 211
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 208
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 205
Liquid biopsy for lung cancer early detection 201
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 200
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 198
Applications of genomics in NSCLC 197
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 191
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 185
One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable Tumor-node-metastasis staging 180
Immunotherapeutic Advances for NSCLC 176
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 170
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 170
ADCs and TCE in SCLC Therapy: The Beginning of a New Era? 167
Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway 165
Targeted drugs in small-cell lung cancer 162
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 162
Activation of viral defense signaling in cancer 162
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer 161
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path? 160
Age-related genetic abnormalities: the Achilles’ heel for customizing therapy in elderly lung cancer patients 156
Advances in immunotherapy for treatment of lung cancer 155
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 154
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 149
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 139
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 137
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 136
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) 136
Liquid biopsy in non-small cell lung cancer: a comparison between different methodologies to detect somatic mutations 136
Adaptive Resistance Mechanisms in EGFR Mutant NSCLC 135
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance 130
Emerging drugs for non-small-cell lung cancer. 130
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 130
On the pharmacogenetics of non-small cell lung cancer treatment 129
Polymorphisms in DNA repair genes modulate survival incisplatin/gemcitabine-treated non-small-cell lung cancer patients 126
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 126
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 125
Molecular characterization of synchronous sporadic colorectal carcinomas 123
'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research' 123
A friendly approach to pesonalized treatment in lung adenocarcinoma. REVISTA COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA 123
MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment 122
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 122
PIK3CA mutations in breast cancer: a potential marker 120
DNA repair and mitotic checkpoint genes as potential predictors of chemotherapy response in non-small-cell lung cancer. 120
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance 118
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 118
Beyond platinum treatment for NSCLC: what does the future hold? 118
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review 117
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 117
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives 117
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 117
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? 116
Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient 116
Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC 116
Non-small-cell lung cancer signaling pathways, metabolism, and PD-1/PD-L1 antibodies 116
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma 115
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 115
Feasibility of cell-free circulating tumor DNA testing for lung cancer 114
Rare histotypes of epithelial biliary tract tumors: A literature review 114
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 113
Usefulness of predictive tests for cancer treatment 112
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need 111
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma 110
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? 110
Human endogenous retroviruses and cancer 109
History of extensive disease small cell lung cancer treatment: Time to raise the bar? a review of the literature 109
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 108
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. 108
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 107
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient 106
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints 102
Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data Through a Retrospective Disproportionality Analysis (2014–2023) 101
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 100
The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC 100
Immunotherapy in NSCLC: A promising and revolutionary weapon 100
PIK3CA mutations in breast cancer: A potential predictive marker 99
Melanoma: oncogenic drivers and the immune system 99
Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities 98
Genistein and Curcumin Inhibit Proliferation and Invasiveness in BRAFV600E Mutant and Wild-Type Melanoma Cells: Insights into Their Anticancer Effects 98
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive 98
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response 98
Targeting MET amplification in EGFR-mutant non-small-cell lung cancer 98
Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives 97
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 97
Other targeted drugs in melanoma 96
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 96
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 95
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 95
Predicting the outcome of chemotherapy for lung cancer. 94
Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP) 93
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape 93
Totale 13.993
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.590
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.590
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022690 0 0 0 0 22 14 39 30 8 94 188 295
2022/20231.804 153 144 65 142 100 179 47 76 837 11 39 11
2023/2024551 34 75 40 41 38 132 33 28 13 29 4 84
2024/20252.932 47 31 66 145 155 110 76 646 727 204 258 467
2025/20269.015 390 562 720 713 667 1.787 1.061 1.065 1.092 478 214 266
2026/20272.369 284 795 567 662 61 0 0 0 0 0 0 0
Totale 19.506